BioMarin Pharmaceutical misses Q3 revenue estimates, revises annual revenue forecast

BioMarin Pharmaceutical

27/10/2025 20:12

Overview

BioMarin Q3 revenue rose 4% yr/yr, but missed analyst expectations

Adjusted EPS for Q3 missed analyst expectations

Company plans to divest ROCTAVIAN, aligning with strategic focus

Outlook

BioMarin raises full-year 2025 total revenue guidance at the midpoint

Company reaffirms full-year 2025 VOXZOGO revenue outlook of $900 mln to $935 mln

Non-GAAP Operating Margin guidance updated to 26%-27% for 2025

Result Drivers

PALYNZIQ AND VOXZOGO GROWTH - Over 20% revenue growth driven by new patient initiations across all regions

STRATEGIC FOCUS - Co focuses on Enzyme Therapies and Skeletal Conditions as central to growth strategy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$776 mln
$780.62 mln (20 Analysts)
Q3 Adjusted EPS
Miss
$0.12
$0.37 (17 Analysts)
Q3 EPS
-$0.16
Q3 Net Income
-$31 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $95.00, about 42.7% above its October 24 closing price of $54.48

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nPn1B01ZXa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)